Over-expression of ASIC1a promotes proliferation via activation of the β-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer

Cheng Jin; Feng-Lai Yuan; Yuan-Long Gu; Xia Li; Min-Feng Liu; Xiao-Min Shen; Bo Liu; Mao-Qun Zhu

doi:10.18632/oncotarget.10774

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Over-expression of ASIC1a promotes proliferation via activation of the β-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer

Cheng Jin _, Feng-Lai Yuan, Yuan-Long Gu, Xia Li, Min-Feng Liu, Xiao-Min Shen, Bo Liu and Mao-Qun Zhu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:25977-25988. https://doi.org/10.18632/oncotarget.10774

Metrics: PDF 3224 views | HTML 2707 views | ?

Abstract

Cheng Jin1, Feng-Lai Yuan2, Yuan-Long Gu1, Xia Li2, Min-Feng Liu1, Xiao-Min Shen1, Bo Liu1, Mao-Qun Zhu1

1Department of Hepatobiliary Pancreatic Center, The Third Hospital Affiliated to Nantong University, Wuxi, 214041, Jiangsu, China

2Department of Research Institute, The Third Hospital Affiliated to Nantong University, Wuxi, 214041, Jiangsu, China

Correspondence to:

Cheng Jin, email: [email protected]

Keywords: ASIC1a, β-catenin, CRISPR/CAS9, liver cancer, proliferation

Received: February 16, 2016 Accepted: June 04, 2016 Published: July 22, 2016

ABSTRACT

Acid-sensing ion channels 1a (ASIC1a) has been reported to promote migration and invasion in liver cancer. However, the clinical significance and molecular mechanism of ASIC1a in liver cancer remain unknown. In the study, we found that ASIC1a is frequently up-regulated in liver cancer tissues. The over-expression of ASIC1a is associated with advanced clinical stage and poor prognosis. The pro-proliferative of ASIC1a is pH dependent. Knockout of ASIC1a by CRISPR/CAS9 inhibited liver cancer cell proliferation and tumorigenicity in vitro and in vivo through β-catenin degradation and LEF-TCF inactivation. Our results indicated a potential diagnostic marker and chemotherapeutic target for liver cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10774

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Over-expression of ASIC1a promotes proliferation via activation of the β-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer

Abstract